At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KRBP Kiromic BioPharma, Inc.
Trading 12-24 09:53:11 EST Delay
Kiromic Biopharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01
THOMSON REUTERS  ·  12-12
Kiromic Biopharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01
SEC charges Kiromic Bio with misleading investors about status of FDA reviews
TIPRANKS  ·  12-04
SEC charges Kiromic Bio with misleading investors about status of FDA reviews
Kiromic BioPharma announces settlement of SEC investigation
TIPRANKS  ·  12-04
Kiromic BioPharma announces settlement of SEC investigation
Kiromic Biopharma Inc - SEC Declines to Impose Civil Penalties on Kiromic Biopharma
THOMSON REUTERS  ·  12-04
Kiromic Biopharma Inc - SEC Declines to Impose Civil Penalties on Kiromic Biopharma
Kiromic Biopharma Announces Settlement of Previously Disclosed SEC Investigation
THOMSON REUTERS  ·  12-04
Kiromic Biopharma Announces Settlement of Previously Disclosed SEC Investigation
Kiromic Biopharma Inc - Patient 4 Shows 5.3% Tumor Reduction at Six-Month Follow-up
THOMSON REUTERS  ·  10-08
Kiromic Biopharma Inc - Patient 4 Shows 5.3% Tumor Reduction at Six-Month Follow-up
Kiromic Biopharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01
THOMSON REUTERS  ·  10-08
Kiromic Biopharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01
Kiromic Biopharma Inc - Tumor Size Reduced by 27% in First Patient
THOMSON REUTERS  ·  10-01
Kiromic Biopharma Inc - Tumor Size Reduced by 27% in First Patient
Kiromic Biopharma Inc - Progression-Free Survival Reaches 10 Months With No Adverse Events
THOMSON REUTERS  ·  10-01
Kiromic Biopharma Inc - Progression-Free Survival Reaches 10 Months With No Adverse Events
Kiromic Biopharma Reports Favorable 10-Month Follow-up Results for the First Patient Treated in Its Deltacel-01 Clinical Trial
THOMSON REUTERS  ·  10-01
Kiromic Biopharma Reports Favorable 10-Month Follow-up Results for the First Patient Treated in Its Deltacel-01 Clinical Trial
Kiromic Biopharma Inc - Additional Follow-up Results Expected in October
THOMSON REUTERS  ·  10-01
Kiromic Biopharma Inc - Additional Follow-up Results Expected in October
Kiromic Biopharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
THOMSON REUTERS  ·  09-20
Kiromic Biopharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
Kiromic Biopharma: Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
THOMSON REUTERS  ·  09-19
Kiromic Biopharma: Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Kiromic stock soars 65% on FDA fast track status for Deltacel
seekingalpha  ·  08-15
Kiromic stock soars 65% on FDA fast track status for Deltacel
Kiromic Biopharma’s Deltacel Receives FDA Fast Track Designation
THOMSON REUTERS  ·  08-14
Kiromic Biopharma’s Deltacel Receives FDA Fast Track Designation
Kiromic Biopharma Provides Update on Part 1 of the Deltacel-01 Trial
THOMSON REUTERS  ·  08-09
Kiromic Biopharma Provides Update on Part 1 of the Deltacel-01 Trial
KIROMIC BIOPHARMA TO ADVANCE DELTACEL-01 CLINICAL TRIAL TO PART 2, EXPANSION PHASE
THOMSON REUTERS  ·  07-18
KIROMIC BIOPHARMA TO ADVANCE DELTACEL-01 CLINICAL TRIAL TO PART 2, EXPANSION PHASE
Kiromic Biopharma Provides Updates on Its Deltacel-01 Clinical Trial
THOMSON REUTERS  ·  06-20
Kiromic Biopharma Provides Updates on Its Deltacel-01 Clinical Trial
No data available

Introduction

Company Name.
Kiromic BioPharma, Inc.
Affiliated Markets:
OTCQB
Listing Date:
--
Main Business:
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
Issue price:
--